MOR and COMT SNP Polymorphism and Pain

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-10-31

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with certain polymorphism in the MOR and COMT genes will display differences in their response to analgesics.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Utility of CYP2D6 Genotyping to Improve the Efficacy and Safety of Tramadol

NCT05657704

Post-surgical Pain Pain, Acute Postoperative Pain

UNKNOWN PHASE4

Genetics of Cytochrome CYP2D6 and Effects of Codeine and Tramadol on Postoperative Pain Management

NCT06723379

Post-operative Pain

COMPLETED

Cancer Pain Single Nucleotide Polymorphisms (SNPs)

NCT00956878

Cancer Pain

COMPLETED

Variation of COMT Val158Met Polymorphism Between COM-ON Patients and METHADOSE Patients

NCT01570699

COMPLETED

Genetic Determinants of Amitriptyline Efficiency for Pain Treatment - Part II

NCT02256956

Chronic Pain

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After tissue injury, there is great interindividual variability among patients in the amount of pain experienced (pain intensity and duration of pain) and in the degree of pain relief from analgesics. In experimental settings, Single Nucleotide Polymorphisms (SNP) at the MOR and COMT genes have been found to alter the response to opioids in in vitro models and in human.We will collect clinical data on one hundred patients undergoing surgery. We will obtain DNA extracted via PCR techniques from the patients' blood and we will identify SNPs at the mu opioid receptor and catechol-O-methyltransferase genes. We will analyze the data to search for correlation between clinical patterns of postoperative pain and opioid effects and SNPs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain Relief

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

dosing

SNP genotyping

Intervention Type OTHER

Coded blood specimens will be transported to the Department of Gene Technology TTÜ and genotyping analysis will be performed. Lymphocytes will be isolated from blood specimens using Ficol-Paq gradients, and genomic DNA isolated using a salting-out procedure. Variants of the MOR gene and other genes of interests will be performed by DNA sequence analysis of PCR-amplified DNA, using primers located in flanking intron sequence. All methods proposed are currently in operation in the respective facilities.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SNP genotyping

Coded blood specimens will be transported to the Department of Gene Technology TTÜ and genotyping analysis will be performed. Lymphocytes will be isolated from blood specimens using Ficol-Paq gradients, and genomic DNA isolated using a salting-out procedure. Variants of the MOR gene and other genes of interests will be performed by DNA sequence analysis of PCR-amplified DNA, using primers located in flanking intron sequence. All methods proposed are currently in operation in the respective facilities.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years of age and older
* Give informed consent to participate in this study

Exclusion Criteria

* Neurologic or psychiatric disease sufficient, in the clinical judgment of the investigator, to compromise informed consent or data collection
* ASA classification score 3 or above
* Patients with past or present history of substance abuse.
* Patients with a history of chronic pain requiring daily analgesic use for more then one month.
* Patients with a current diagnosis of anxiety or depression requiring medical treatment
* Patients allergic to morphine

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No